Literature DB >> 4116545

General considerations in the choice and management of regimens of chemotherapy for pulmonary tuberculosis.

W Fox.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1972        PMID： 4116545

Source DB:  PubMed          Journal:  Bull Int Union Tuberc        ISSN： 0074-9249


× No keyword cloud information.
  9 in total

1.  Drug treatment of pulmonary tuberculosis.

Authors:  M Aquinas
Journal:  Drugs       Date:  1975       Impact factor: 9.546

2.  Pharmacokinetics of isoniazid metabolism in man.

Authors:  G A Ellard; P T Gammon
Journal:  J Pharmacokinet Biopharm       Date:  1976-04

3.  Intermittent treatment regimens in pulmonary tuberculosis.

Authors:  M Zierski
Journal:  Lung       Date:  1979       Impact factor: 2.584

Review 4.  New trends in the chemotherapy of tuberculosis--current aspects.

Authors:  M Zierski
Journal:  Pneumonologie       Date:  1974-06-14

5.  Compliance with anti-tuberculous therapy: a field trial of a pill-box with a concealed electronic recording device.

Authors:  R Cheung; J Dickins; P W Nicholson; A S Thomas; H H Smith; H E Larson; A A Deshmukh; R J Dobbs; S M Dobbs
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

6.  A sensitive urine-test method for monitoring the ingestion of isoniazid.

Authors:  G A Ellard
Journal:  J Clin Pathol       Date:  1977-01       Impact factor: 3.411

7.  Address card for obtaining accurate addresses of clinic patients.

Authors:  K V Krishnaswami; M C Satagopan; P R Somasundaram; S P Tripathy; S Radhakrishna; W Fox
Journal:  Br Med J       Date:  1979-01-13

8.  An evaluation of the potential use of isoniazid, acetylisoniazid and isonicotinic acid for monitoring the self-administration of drugs.

Authors:  G A Ellard; P J Jenner; P A Downs
Journal:  Br J Clin Pharmacol       Date:  1980-10       Impact factor: 4.335

9.  Acetylator phenotyping of tuberculosis patients using matrix isoniazid or sulphadimidine and its prognostic significance for treatment with several intermittent isoniazid-containing regimens.

Authors:  G A Ellard; P T Gammon
Journal:  Br J Clin Pharmacol       Date:  1977-02       Impact factor: 4.335
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.